Literature DB >> 26734638

Relationship between serum CA19-9 and CEA levels and prognosis of pancreatic cancer.

Lei Wu1, Peijun Huang1, Fang Wang1, Daqian Li1, Erfu Xie1, Yan Zhang1, Shiyang Pan1.   

Abstract

BACKGROUND: To explore the relationship between preoperative serum CA19-9 and CEA levels and prognosis of pancreatic cancer (PC).
METHODS: The clinicopathological data of 128 patients with pancreatic adenocarcinoma who were treated in our center between January 2012 and December 2013 were retrospectively analyzed. The relationships between serum CA19-9 and CEA levels and survival were analyzed using Kaplan-Meier method, log-rank test, and Cox regression analysis. The cut-off values for serum CA19-9 and CEA levels were 39 U/mL and 4.7 ng/mL, respectively.
RESULTS: Among these 128 patients, the mean age was 62 years, and median survival was 12.2 days. The positive rate of CA19-9 and CEA was 78.1% and 37.5%, respectively. Patients with increased CA19-9 or CEA level suffered a poorer prognosis than those with normal CA19-9 or CEA level (CA19-9: P=0.027; CEA: P=0.036). Cox logistic analysis revealed that lymphatic metastasis, CA19-9 >39 U/mL, and CEA >4.7 ng/mL were independent prognostic factors in patients with pancreatic carcinoma.
CONCLUSIONS: Preoperative serum CA19-9 and CEA level are closely related with survival time in PC patients and therefore may be used for evaluating the prognosis for PC.

Entities:  

Keywords:  CA19-9; CEA; Pancreatic cancer (PC); prognosis

Year:  2015        PMID: 26734638      PMCID: PMC4690989          DOI: 10.3978/j.issn.2305-5839.2015.11.17

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  13 in total

Review 1.  Early detection of pancreatic carcinoma.

Authors:  Christophe Rosty; Michael Goggins
Journal:  Hematol Oncol Clin North Am       Date:  2002-02       Impact factor: 3.722

2.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

3.  A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer.

Authors:  Liang Liu; Huaxiang Xu; Wenquan Wang; Chuntao Wu; Yong Chen; Jingxuan Yang; Putao Cen; Jin Xu; Chen Liu; Jiang Long; Sushovan Guha; Deliang Fu; Quanxing Ni; Aminah Jatoi; Suresh Chari; Angela L McCleary-Wheeler; Martin E Fernandez-Zapico; Min Li; Xianjun Yu
Journal:  Int J Cancer       Date:  2014-10-18       Impact factor: 7.396

4.  Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels.

Authors:  Ming-Chu Chang; Po-Chin Liang; Shiow Jan; Ching-Yao Yang; Yu-Wen Tien; Shu-Chen Wei; Jau-Min Wong; Yu-Ting Chang
Journal:  Pancreatology       Date:  2014-07-25       Impact factor: 3.996

5.  Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis.

Authors:  Zhe Huang; Fang Liu
Journal:  Tumour Biol       Date:  2014-05-01

6.  The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.

Authors:  X G Ni; X F Bai; Y L Mao; Y F Shao; J X Wu; Y Shan; C F Wang; J Wang; Y T Tian; Q Liu; D K Xu; P Zhao
Journal:  Eur J Surg Oncol       Date:  2005-03       Impact factor: 4.424

7.  Serum CA242, CA199, CA125, CEA, and TSGF are Biomarkers for the Efficacy and Prognosis of Cryoablation in Pancreatic Cancer Patients.

Authors:  Ye Chen; She-Gan Gao; Jian-Min Chen; Gong-Ping Wang; Zeng-Fang Wang; Bo Zhou; Can-Hui Jin; Yan-Tong Yang; Xiao-Shan Feng
Journal:  Cell Biochem Biophys       Date:  2015-04       Impact factor: 2.194

8.  [Clinical analysis of 2340 cases of pancreatic cancer].

Authors:  Qun-hua Zhang; Quan-xing Ni
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2004-02-02

Review 9.  Epidemiology of pancreatic cancer.

Authors:  D S Michaud
Journal:  Minerva Chir       Date:  2004-04       Impact factor: 1.000

10.  Cancer statistics for Hispanics/Latinos, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012 Sep-Oct       Impact factor: 508.702

View more
  16 in total

1.  Preoperative CA19-9: a competitive predictor of recurrence in patients with colorectal cancer liver metastases after hepatectomy.

Authors:  Jia-Ming Liu; Yan-Yan Wang; Wei Liu; Da Xu; Kun Wang; Bao-Cai Xing
Journal:  Int J Colorectal Dis       Date:  2021-01-09       Impact factor: 2.571

2.  Prediction of Angiopoietin-like Protein 4-related Signaling Pathways in Cholangiocarcinoma Cells.

Authors:  Tin May Aung; Atit Silsirivanit; Apinya Jusakul; Waraporn Chan-On; Tanakorn Proungvitaya; Sittiruk Roytrakul; Siriporn Proungvitaya
Journal:  Cancer Genomics Proteomics       Date:  2022 Jul-Aug       Impact factor: 3.395

3.  Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer.

Authors:  Soichiro Ako; Hironari Kato; Kazuhiro Nouso; Hideaki Kinugasa; Hiroyuki Terasawa; Hiroshi Matushita; Saimon Takada; Yosuke Saragai; Sho Mizukawa; Shinichiro Muro; Daisuke Uchida; Takeshi Tomoda; Kazuyuki Matsumoto; Shigeru Horiguchi; Daisuke Nobuoka; Ryuichi Yoshida; Yuzo Umeda; Takahito Yagi; Hiroyuki Okada
Journal:  Cancer Biol Ther       Date:  2021-10-10       Impact factor: 4.875

Review 4.  Biomarkers in pancreatic adenocarcinoma: current perspectives.

Authors:  Douglas S Swords; Matthew A Firpo; Courtney L Scaife; Sean J Mulvihill
Journal:  Onco Targets Ther       Date:  2016-12-09       Impact factor: 4.147

Review 5.  New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.

Authors:  Isabel Corraliza-Gorjón; Beatriz Somovilla-Crespo; Silvia Santamaria; Jose A Garcia-Sanz; Leonor Kremer
Journal:  Front Immunol       Date:  2017-12-21       Impact factor: 7.561

6.  Development and Validation of a Nomogram for Predicting Survival in Patients with Advanced Pancreatic Ductal Adenocarcinoma.

Authors:  Qing-Long Deng; Shu Dong; Lei Wang; Chen-Yue Zhang; Hai-Feng Ying; Zhao-Shen Li; Xiao-Heng Shen; Yuan-Bao Guo; Zhi-Qiang Meng; Jin-Ming Yu; Qi-Wen Chen
Journal:  Sci Rep       Date:  2017-09-14       Impact factor: 4.379

Review 7.  Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma.

Authors:  John C Chang; Madappa Kundranda
Journal:  Int J Mol Sci       Date:  2017-03-20       Impact factor: 5.923

8.  Risk factors of liver metastasis from advanced pancreatic adenocarcinoma: a large multicenter cohort study.

Authors:  Dong S; Wang L; Guo Y B; Ying H F; Shen X H; Meng Z Q; Chen Hao; Chen Q W; Li Z S
Journal:  World J Surg Oncol       Date:  2017-07-03       Impact factor: 2.754

Review 9.  Blood-based Markers in the Prognostic Prediction of Esophagogastric Junction Cancer.

Authors:  Can-Tong Liu; Chao-Qun Hong; Xu-Chun Huang; En-Min Li; Yi-Wei Xu; Yu-Hui Peng
Journal:  J Cancer       Date:  2020-04-27       Impact factor: 4.207

10.  Identifying the Best Marker Combination in CEA, CA125, CY211, NSE, and SCC for Lung Cancer Screening by Combining ROC Curve and Logistic Regression Analyses: Is It Feasible?

Authors:  Qixian Yang; Ping Zhang; Rongqiang Wu; Kefeng Lu; Hongxing Zhou
Journal:  Dis Markers       Date:  2018-10-01       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.